Chromatography Online

Looking Ahead in GLP-1 Development

The speakers highlight emerging trends in GLP-1 therapy, including personalized dosing, weight maintenance, combination ...
The Manila Times

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1Holistic ...
Medscape

ADA 2026 Standards of Care Target Implementation, Policy

The 2026 update to the ADA’s Standards of Care in Diabetes introduces new guidance on a wide range of topics, including the ...
Healio

Glycemic management with cancer therapy, CGM use among 2026 ADA Standards of Care updates

New recommendations on glycemic management for people with cancer, continuous glucose monitoring and the use of ...
New Scientist

Too busy to meditate? Microdosing mindfulness has big health benefits

Small bursts of mindfulness practices lasting a minute or less can have unexpected benefits for those with busy lives - ...
Le Lézard

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine (FFA) in children and adults with CDKL5 ...

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Syndax Pharmaceuticals, Inc. ( SNDX) The 67th American Society of Hematology ( ASH) Annual Meeting December 8, 2025 7:00 AM EST ...